

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-23. Canceled.

24. (previously presented) A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic chosen from azithromycin or clarithromycin or an immunosuppressive macrolide chosen from sirolimus, FK506 or SDZ ASM 981, and a permeation modulator which are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced.

25. (previously presented) The formulation of claim 24 comprising up to 10% by weight of the macrocyclic lactone antibiotic or the immunosuppressive macrolide or analogue, derivative or pro-drug thereof and 1 to 60% by weight of the permeation modulator.

26. (canceled).

27. (canceled).

28. (canceled).

29. (canceled).

30. (previously presented) The formulation of claim 24 wherein the dermatological condition is psoriasis, alopecia, eczema dermatitis, lichen planus, lupus erthematosus, pyderma gangrenosum, vitiligo, graft versus host disease, pustular skin infections, bacterial skin infections or acne vulgaris.

31. (previously presented) The formulation of claim 30 wherein the dermatological condition is eczema dermatitis and the concentration of macrocyclic lactone antibiotic or immunosuppressive macrolide is 0.05% to 2% by weight.

32. (canceled).

33. (canceled).

34. (canceled).

35. (canceled).

36. (canceled).

37. (previously presented) The formulation of claim 24 further comprising a thickening agent.

38. (previously presented) The formulation of claim 37 wherein the thickening agent is white soft paraffin, cetostearyl alcohol, yellow soft paraffin, cetyl alcohol, steryl alcohol, divalent carboxylic acid soaps or carnauber wax.

39. (previously presented) A method for the treatment of a dermatological condition comprising administering an effective amount of the topical formulation of claim 24.

40. (previously presented) A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic chosen from azithromycin or clarithromycin or an immunosuppressive macrolide chosen from sirolimus, FK506 or SDZ ASM 981, and a permeation modulator which are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced and wherein the permeation modulator is used in conjunction with a solvent system comprising an aromatic alcohol or a biologically acceptable benzene derivative, with or without an admixture of monoglycerides and a fatty acid ester.

41. (previously presented) The formulation of claim 40 wherein the solvent system comprises an aromatic alcohol or a biologically acceptable benzene derivative, with or without an admixture of a fatty acid ester.

42. (previously presented) The formulation of claim 40 wherein the permeation modulator comprises capric acid and the solvent system comprises benzyl alcohol.

43. (previously presented) The formulation of claim 40 wherein the concentration of the solvent system is 5% to 90% by weight.

44. (previously presented) The formulation of claim 40 further comprising a thickening agent.

45. (previously presented) The formulation of claim 44 wherein the thickening agent is white soft paraffin, cetostearyl alcohol, yellow soft paraffin, cetyl alcohol, steryl alcohol, divalent carboxylic acid soaps or carnauber wax.

46. (previously presented) A method for the treatment of a dermatological condition comprising administering an effective amount of the topical formulation of claim 40.

47. (previously presented) The formulation of claim 40 comprising up to 10% by weight of the macrocyclic lactone antibiotic or the immunosuppressive macrolide or analogue, derivative or pro-drug thereof and 1 to 60% by weight of the permeation modulator.

48. (previously presented) The formulation of claim 40 wherein the permeation modulator is an alkanoic acid or alkenic acid.

49. (previously presented) The formulation of claim 48 wherein the alkanoic acid or alkenic acid is capric acid, octanoic acid or oleic acid.

50. (previously presented) The formulation of claim 40 wherein the dermatological condition is psoriasis, alopecia, eczema dermatitis, lichen planus, lupus erthematosus, pyderma gangrenosum, vitiligo, graft versus host disease, pustular skin infections, bacterial skin infections or acne vulgaris.

51. (previously presented) The formulation of claim 50 wherein the dermatological condition is eczema dermatitis and the concentration of macrocyclic lactone antibiotic or immunosuppressive macrolide is 0.05% to 2% by weight.

52. (new) The formulation of claim 24 wherein the macrocyclic lactone antibiotic is azithromycin.

53. (new) The formulation of claim 24 wherein the macrocyclic lactone antibiotic is azithromycin and wherein the permeation modulator is an alkanolic acid or alkenic acid.

54. (new) The formulation of claim 53 wherein the alkanolic acid or alkenic acid is capric acid, octanoic acid or oleic acid.

55. (new) The formulation of claim 24 wherein the macrocyclic lactone antibiotic is clarithromycin.

56. (new) The formulation of claim 24 wherein the macrocyclic lactone antibiotic is clarithromycin and wherein the permeation modulator is an alkanolic acid or alkenic acid.

57. (new) The formulation of claim 56 wherein the alkanolic acid or alkenic acid is capric acid, octanoic acid or oleic acid.

58. (new) The formulation of claim 24 wherein the immunosuppressive macrolide is sirolimus.

59. (new) The formulation of claim 24 wherein the immunosuppressive macrolide is sirolimus and wherein the permeation modulator is an alkanoic acid or alkenic acid.

60. (new) The formulation of claim 59 wherein the alkanoic acid or alkenic acid is capric acid, octanoic acid or oleic acid.

61. (new) The formulation of claim 24 wherein the immunosuppressive macrolide is FK506.

62. (new) The formulation of claim 24 wherein the immunosuppressive macrolide is FK506 and wherein the permeation modulator is an alkanoic acid or alkenic acid.

63. (new) The formulation of claim 62 wherein the alkanoic acid or alkenic acid is capric acid, octanoic acid or oleic acid.

64. (new) The formulation of claim 24 wherein the immunosuppressive macrolide is SDZ ASM 981.

65. (new) The formulation of claim 24 wherein the immunosuppressive macrolide is SDZ ASM 981 and wherein the permeation modulator is an alkanoic acid or alkenic acid.

66. (new) The formulation of claim 65 wherein the alkanoic acid or alkenic acid is capric acid, octanoic acid or oleic acid.